Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Siddharth Wayangankar

Interventional Cardiology Jacksonville, FL Medical Doctor

NPI 1386804565 CMS profile 17145

836 Prudential Dr Ste 1700, Jacksonville, FL 32207

Open in the dashboard

General payments

$1,159,487

1,778 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$166,580 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Siddharth Wayangankar of Jacksonville, FL is reported in the CMS Open Payments database as having received $1,159,487 across 1,778 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $166,580 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $104,503 250
2024 General $141,575 287
2023 General $106,326 278
2022 General $152,711 246
2021 General $134,486 175
2020 General $201,874 209
2019 General $318,011 333

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Siddharth Wayangankar
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Siddharth Wayangankar were reported at $104,503. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Siddharth Wayangankar Interventional Cardiology median Middle half National median
2019 $318,011 $1,097 $329–$3,048 $163
2020 $201,874 $473 $161–$1,480 $114
2021 $134,486 $677 $233–$1,827 $132
2022 $152,711 $978 $333–$2,724 $149
2023 $106,326 $1,136 $382–$2,986 $160
2024 $141,575 $1,181 $395–$3,326 $164
2025 $104,503 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $569,552 659 payments
  2. Medtronic Vascular, Inc. $368,739 366 payments
  3. Arrow International, Inc. $65,102 19 payments
  4. Abiomed $50,859 122 payments
  5. Abbott Laboratories $42,570 243 payments
  6. Medtronic, Inc. $36,137 78 payments
  7. Penumbra, Inc. $10,952 39 payments
  8. Teleflex LLC $9,938 39 payments
  9. Boston Scientific Corporation $2,091 90 payments
  10. Shockwave Medical, Inc $415 12 payments
  11. Other $3,131 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $474,588 121 payments
  2. Consulting Fee $385,519 96 payments
  3. Travel and Lodging $168,680 372 payments
  4. Honoraria $60,650 20 payments
  5. Food and Beverage $46,799 1,160 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $23,250 8 payments
  7. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. CoreValve Evolut Transcatheter Valve Systems $366,321 322 payments
  2. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $335,076 234 payments
  3. Edwards SAPIEN 3 Transcatheter Heart Valve $140,938 127 payments
  4. MANTA $70,170 46 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $58,006 72 payments
  6. Impella $50,076 111 payments
  7. CoreValve Evolut Transcatheter Valve Systems $32,791 26 payments
  8. NAVITOR $22,786 30 payments
  9. Indigo System $9,695 35 payments
  10. SAPIEN 3 Ultra RESILIA $7,783 156 payments
  11. Other $37,770 532 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

164

Median for Interventional Cardiology: 2,236

Drug cost

$1,861

Median for Interventional Cardiology: $380,412

Branded share of claims

65.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 108 $1,013
Enoxaparin Sodium Generic 18 $583
Atorvastatin Calcium Generic 24 $189
Lisinopril Generic 14 $76

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$475,778

Medicare's payments for the services billed

Medicare patients

1,657

Average age 77

Services billed

4,794

794 women, 863 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Arthritis 57%
Heart failure 54%
Atrial fibrillation 48%
Diabetes 47%
Chronic kidney disease 46%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$35 — —
LEQVIO
$30 — —
ENTRESTO
$30 — —
XARELTO
$24 — —
VYNDAQEL
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

1,778 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record